Anlon Healthcare IPO is all set to open for subscription on August 26, 2025, and it will close on August 29, 2025. Anlon Healthcare Limited, incorporated in 2013, is a chemical manufacturing company engaged in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs).
This blog will cover all the Anlon Healthcare IPO details, including issue size, price band, minimum investment amount for different investors, financial performance, and risk factors.
Anlon Healthcare IPO Date
The key pointers for the Anlon Healthcare IPO dates are:
- Bidding Opening Date: August 26, 2025
- Bidding Closing Date: August 29, 2025
- Allotment Date: September 1, 2025
- Initiation of Refunds (in case of less or no allotment): September 2, 2025
- Shares Credited to Your Demat Account: September 2, 2025
- IPO Listing Date: September 3, 2025
- Listing on Exchange: BSE and NSE
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Anlon Healthcare: IPO Issue Size
Anlon Healthcare IPO valuation, as denoted by the market capitalization, stood at ₹483.68 crores. Here are the important details:
- Anlon Healthcare IPO Price Band: ₹86 to ₹91 per share
- Lot Size: 164 Shares
- Issue Size and Amount: 1.33 crore shares (₹121.03 crores)
- Fresh Issue Size and Amount: 1.33 crore shares (₹121.03 crores)
Anlon Healthcare IPO Proceeds Usage
The net proceeds from the Anlon Healthcare IPO are proposed to be utilised for the following purposes:
- Funding the capital expenditure requirements for the expansion of the manufacturing facility.
- Repayment or prepayment of certain outstanding secured borrowings (term loan) availed by the company.
- Meeting the working capital requirements of the company.
- For other corporate purposes
Anlon Healthcare IPO Reservations
Anlon Healthcare IPO reservations to different investors are:
- For QIBs: Not less than 75% of the Net Issue
- For NIIs: Not more than 15% of the Net Issue
- For Retail Investors: Not more than 10% of the Net Issue
Anlon Healthcare IPO Lot Size
Anlon Healthcare IPO lot size is 164 shares, wherein bidding can be done in multiples. The minimum amount that each category of investor needs to bid in this IPO is:
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
Anlon Healthcare IPO Details: Promoter Holding
Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia are the promoters of the company.
Anlon Healthcare Limited: Company Overview
Anlon Healthcare Limited is a chemical manufacturing company that produces:
- High-purity pharmaceutical intermediates: They are used as raw materials in making Active Pharmaceutical Ingredients (APIs).
- Active Pharmaceutical Ingredients (APIs): These are used as raw materials in pharmaceutical formulations for various Finished Dosage Forms (FDF), such as tablets, capsules, ointments, syrups, and more.
Product Portfolio
The company’s portfolio includes pharmaceutical intermediates, APIs, nutraceutical APIs, and ingredients for personal care and veterinary uses. All APIs are made according to the Indian and international pharmacopeia standards.
The product portfolio includes 65 commercial products, 28 products in the pilot stage, and 49 products in laboratory testing or development at a small scale.
Other Products and Services
Anlon Healthcare Limited is one of the few Indian manufacturers of Loxoprofen Sodium Dihydrate, an active pharmaceutical ingredient used for treating pain and inflammation. This includes conditions like arthritis, back pain, and recovery after surgery.
It also provides custom manufacturing services for complex compounds, which ensures higher purity levels. Additionally, it assists with API development and Drug Master File (DMF) filings for both domestic and international markets.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Overseas Presence
Apart from domestic markets, products are also supplied to international markets to pharmaceutical companies, third-party dealers, and distributors.
The company has also expanded operations beyond India to over 15 countries, including Italy, Germany, China, Argentina, Japan, Brazil, United Kingdom, UAE, etc. In FY25, the company exported its products to 15 countries.
Anlon Healthcare IPO: Financial Performance
Anlon Healthcare Ltd. key financials for different periods are as follows:
| Particulars (in ₹ Cr) | FY25 | FY24 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 120.29 | 66.58 | 81% |
| EBIDTA | 32.38 | 15.57 | 108% |
| Net Profit | 20.52 | 9.66 | 112% |
| Net Cash from Operating Activities | -22.55 | -3.23 | 599% |
| Return on Capital Employed (in %) | 21.93% | 16.29% | 6% |
| Debt-Equity Ratio | 0.73 | 3.55 | -2.82 |
- Anlon Healthcare Limited’s revenue from operations increased by 81% YoY to ₹120.29 crores in FY25, driven by strong operational growth.
- EBIDTA grew by 108% to ₹32.38 crores in FY25, indicating improved cost efficiency and higher revenue.
- Net profit rose by 112% YoY to ₹20.52 crores in FY25, supported by strong margins and better operational performance.
- Net Cash Outflow from Operating Activities surged by 599%, reaching ₹22.55 crores in FY25.
- Return on Capital Employed (ROCE) increased to 21.93% in FY25, reflecting better use of capital.
- Debt-Equity Ratio fell significantly from 3.55 in FY24 to 0.73 in FY25, highlighting substantial debt reduction and a stronger balance sheet.
Anlon Healthcare IPO: Peer Comparison
Here is the competitor analysis of Anlon Healthcare Limited:
| Company Name (FY25) | EPS (₹) | P/E (x) | RoNW (%) |
|---|---|---|---|
| Anlon Healthcare Limited | 6.38 | 17.67 | 25.51 |
| Kronox Lab Sciences Limited | 6.91 | 26.18 | 28.26 |
| Acutaas Chemicals Limited | 19.81 | 58.47 | 12.15 |
| Supriya Lifesciences Limited | 23.35 | 29.27 | 18.86 |
- Anlon Healthcare Limited’s EPS is ₹6.38, which is lower than the EPS of Kronox, Acutaas, and Supriya. This indicates potential space for earnings growth.
- Anlon has a P/E ratio of 17.67, which is more reasonable compared to Kronox at 26.18, Supriya at 29.27, and Acutaas at 58.47.
- In terms of profitability, Anlon reports a strong RoNW of 25.51%. This outperforms Acutaas at 12.15% and Supriya at 18.86%, while being close to Kronox at 28.26%. This reflects Anlon’s efficient use of its equity.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Anlon Healthcare IPO Risk Factors
Anlon Healthcare IPO is exposed to various risk factors that can eventually affect its business and investors’ perception:
- The company follows strict quality standards and undergoes regular audits by customers. Not meeting these standards could result in order cancellations, warranty claims, or harm to its reputation.
- A temporary shutdown of the manufacturing facility could disrupt production, affect the supply chain, and harm operations.
- Revenue is dependent on a small number of customers, so losing a major customer could hurt revenue, profitability, and cash flow.
- A large part of revenue comes from the pharmaceutical industry, making the business vulnerable to changes in demand or the obsolescence of products due to new drug development.
For all the insights on Anlon Healthcare IPO and detailed expert advice, you can download the SMC ACE App or visit the SMC telegram channels. Take smart decisions and apply for the Anlon Healthcare IPO easily on the SMC ACE Apply by opening free demat account now.
Frequently Asked Questions – FAQs
1. What are the IPO dates for Anlon Healthcare Limited?
The IPO will open for subscription on August 26, 2025, and closes on August 29, 2025. Allotment is expected to be finalised on September 1, 2025, and the tentative listing date is September 3, 2025, on both BSE and NSE.
2. What is the price band and lot size of the Anlon Healthcare IPO?
The IPO price band is fixed at ₹86 to ₹91 per share. The lot size is 164 shares, and retail investors can apply with a minimum investment of ₹14,924.
3. What is the total issue size of the Anlon Healthcare IPO?
The issue size consists of 1.33 crore shares, aggregating up to ₹121.03 crores. This IPO is a completely fresh issue.
4. How will Anlon Healthcare utilise the IPO proceeds?
The net proceeds will be used for:
- Funding expansion-related capital expenditure
- Repayment or prepayment of secured borrowings
- Meeting working capital requirements
- General corporate purposes
5. Who are the promoters of Anlon Healthcare Limited?
The promoters of the company are Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia.
Reference:
https://www.sebi.gov.in/filings/public-issues/aug-2025/anlon-healthcare-limited-rhp_96196.html
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
